In a study involving 80 patients with non-healing diabetic foot ulcers (DFUs), the use of dehydrated human amnion and chorion allograft (dHACA) showed promising results. Results revealed that 85% of DFUs treated with dHACA healed within 12 weeks, compared to only 33% treated with standard care alone. Additionally, patients receiving dHACA experienced faster healing, with wounds improving in 37 days on average, compared to 67 days with standard care. These findings suggest that dHACA may significantly expedite the healing process for DFUs compared to standard care methods.
This randomized controlled trial investigated the efficacy and safety of weekly and biweekly applications of dehydrated human amnion and chorion allograft (dHACA) alongside standard care versus standard care alone for chronic venous leg ulcers. Conducted across eight wound care centers in the United States, the trial yielded compelling results. Notably, at the 12-week mark, a significantly higher percentage of venous leg ulcers were healed in the dHACA-treated groups compared to the standard-of-care group. This outcome underscores the potential of dHACA as a beneficial and secure treatment option for chronic venous leg ulcers. Learn more about these groundbreaking research findings and their implications for wound care management in this comprehensive study.
Interim results from this multicenter randomized controlled study in VLUs demonstrate that dHACA results in greater patients healed within 12 weeks whencompared to standard multi-layer compression therapy, and significantly improves patients’ healing trajectory over time. These initial data suggest that dHACAserves to benefit patients previously failing to heal with the standard of care
Chronic wounds are associated with considerable patient morbidity and present a significant economic burden to the healthcare system. Often, chronic wounds are in a state of persistent inflammation and unable to progress to the next phase of wound healing. Placental-derived biomaterials are recognized for their biocompatibility, biodegradability, angiogenic, anti-inflammatory, antimicrobial, antifibrotic, immunomodulatory, and immune privileged properties. As such, placental-derived biomaterials have been used in wound management for more than a century.
Chronic diabetic foot ulcers (DFUs) remain a challenge for physicians to treat. High mortality rates for DFU patients have pointed to the low effectiveness of standard care and lack of quality wound care products. The composition (collagen-rich tissue matrix and endogenous growth factors and cells) and functional properties (anti-inflammatory, anti-bacterial, and angiogenic) of placental membranes are uniquely suited to address the needs of chronic wounds. This led to the commercialization of placental membranes, which are now widely available to physicians as a new advanced wound treatment option.
